Clinical trial · Observational
CT Volume Measurement of Hepatocellular Carcinoma
Ct Volume Measurement of Hepatocellular Carcinoma After Transarterial Chemoembolization (TACE) or Microwave Ablation (MWA)
NCT07183566CI-TRIAL-00095410not yet recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The aim of this study is to evaluate the role of CT volumetric measurement in assessing treatment response of hepatocellular carcinoma (HCC) following trans arterial chemoembolization (TACE) or microwave ablation (MWA)
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| CT | — | UNRESOLVED | — |
| Hepatocellular Carcinoma (HCC) | Hepatocellular Carcinoma | ONTOLOGY_EXACT | 0.85 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Ct | Device | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Ct volume measurent of hepatocellular carcinoma after Transarterial chemoembolization or microwave ablation
- timeFrame
- Baseline
- description
- At enrollment, all patients will undergo a comprehensive clinical assessment, including full medical history with emphasis on risk factors for hepatocellular carcinoma triphasic CT scan of the liver, which will serve as the reference for tumor volume (by cm3 or cc), number, and distribution prior to TACE or MWA.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Adult patients (≥18 years) with a confirmed diagnosis of HCC based on AASLD or EASL criteria. * Patients deemed unresectable by the multidisciplinary tumor board. * Patients scheduled for TACE as the primary locoregional therapy. * Preserved liver function (Child-Pugh class A or B). * Adequate renal function to permit contrast-enhanced CT. Exclusion Criteria: * Patients with extrahepatic metastases or portal vein thrombosis. * Patients with contraindications to iodinated contrast or TACE. * Patients with severe comorbid illness that precludes participation. * Patients refuse to provide informed consent.
References
Publications (0)
Data not yet available
No reference posted for this study.